β Scribed by Jay B Lichter; Janice H Kurth
No coin nor oath required. For personal study only.
Pharmacogenetics has been promoted as potentially providing benefits to patients, managed care organizations and pharmaceutical companies. This has not translated into products that benefit healthcare developers, providers or consumers. The reasons for this are many, but this will change as the financial incentives become clear for the pharmaceutical industry to develop products that use genetic susceptibility as part of the rationale for products, healthcare providers have increasing incentive to reduce costs, and patients demand up-to-date technologies to optimize healthcare. Recent studies have established genetic contributions that alter the response to therapy for some disease entities, and more will follow as pharmacogenetics becomes increasingly accepted as an important consideration in the therapeutic decision-making process.
π SIMILAR VOLUMES
## Abstract The psychological impact of military experience on healthcare providers has received little attention to date. The 2005 Department of Defense Survey of Health Related Behaviors Among Active Duty Personnel was used as a secondary data source, and deployed healthcare officers and healthca
## SUMMARY This paper analyzes the empirical relationship between health knowledge and the probability of adopting the lifestyles known as the βAlameda Sevenβ. I test whether having accumulated such knowledge during training in a healthcare profession changes individual lifestyles using the Swiss H